= 0.56). We 14 ± 4/6 ± 2 (P Ͻ 0.01/P Ͻ 0.01), not significantly different between the two agents. Heart rate was decreased by conclude that the effect of antihypertensives on plasma ANP is independent of their action on BP, but dependent atenolol (−16 ± 4 bpm, P Ͻ 0.01) but not by zofenopril (+1 ± 2 bpm, ns). Atenolol increased ANP in all patients on an interaction between the type of drug employed and those clinical characteristics of the patient that but one (⌬ = +42 ± 9 pg/ml, P Ͻ 0.01), while zofenopril did not change it significantly (−6 ± 6 pg/ml), due to 15 reflect pre-existing hypertensive target organ damage. patients exhibiting decreases and 10 increases in
Introduction
are predicted by pretreatment left ventricular funcThe effects of beta-blockers and angiotensin-contion of hypertensives. 9 It is therefore conceivable verting enzyme (ACE) inhibitors on the circulating that individual ANP responses to beta-blockers are levels of plasma atrial natriuretic peptide (ANP) are determined by an interaction between these drugs highly variable. A frequent response to beta-blockers and pre-existing clinical characteristics of the is an increase in plasma ANP, which has been patients. observed in spontaneously hypertensive rats, 1 norAn approximately equal number of studies mal human volunteers, 2 and hypertensive patients. 3 reporting effects of ACE inhibitors on plasma ANP It has been proposed that this effect of beta-blockers have found either decreased or unchanged levels of may play a role in mediating their antihypertensive the natriuretic peptide. They include observations action. 3, 4 However, the ANP response to beta-blockin patients 10, 11 or rats 12, 13 with left ventricular dysade is far from consistent. There are many reports function, humans 14, 15 or rats 16, 17 with hypertension, of unaltered plasma levels of ANP after use of betaand normal subjects. 18, 19 A few authors have blockers in patients with heart disease, 5 hypertendescribed increased plasma ANP or ANP/ sion, 6 renal replacement therapy 7 and cardiac transpulmonary capillary wedge pressure ratios after plantation. 8 An explanation for the presence or ACE inhibition, both in hypertensive subjects and absence of a stimulatory effect of beta-blockers on cardiac patients. 20, 21 In those studies in which mean plasma ANP is not readily apparent; both effects ANP levels are unmodified by ACE inhibitors, the have been reported with the same drug, 2, 8 with variance of ANP is usually very large, reflecting agents sharing the same pattern of cardioselectivresponses of opposite direction (ie, increases and ity, 3, 7 and in the same disease state. 3, 6 Post-exercise decreases) among the subjects studied. 19 The reason for these highly variable results is unknown, but there are observations suggesting that patients' 22 the decrease in incubation at 37°C, pH 5.5) using a rabbit antibody raised in our laboratory. Blood samples for ANP plasma ANP produced by ramipril in patients with congestive heart failure depends on the reductions were collected in chilled tubes containing EDTA, aprotinin and PMSF. They were processed in similar in pulmonary and right atrial pressures, 23 and the changes in ANP by lisinopril in patients with fashion and kept frozen until measurement. The radioimmunoassay has been previously described in ischaemic heart disease correlate with observed changes in renal function due to this agent. 24 detail. 25 In brief, acidified plasma (pH 4) was extracted with Sep-Pak C-18 cartridges (recovery To investigate our hypothesis that ANP responses to antihypertensives depend on an interaction 78%), eluted, freeze dried and resuspended in buffer at pH 7.4. The tracer, 125 I-labeled human ANP, was between the type of agent used and clinical characteristics of the patients, we randomized 34 essential prepared by the lactoperoxidase method and the antibody was purchased from Peninsula (Belmont, hypertensive subjects to receive either the ␤1-selective beta-blocker atenolol, or the ACE inhibitor CA, USA by use of a statistical package (SAS Institute Inc, Cary, NC, USA). For all these analyses, a probability Patients were advised to restrict their salt intake but no specific diet was given. Five patients did not value of Ͻ0.05 was used to reject the null hypothesis. The stepwise (forward) and rsquare promeet the criteria for sustained hypertension (mean of three seated diastolic BPs Ͼ95 mm Hg on two cedures of the general linear model in the SAS package were used for model fitting. Dummy variables consecutive visits), and were therefore discontinued from the study. At the end of the placebo phase, the were used to represent atenolol and zofenopril. In the stepwise forward selection procedure, variremaining 34 patients had: (a) an electrocardiogram scored for left ventricular hypertrophy (LVH) by use ables were entered in the model if the significance level for their F statistic was Ͻ0.05. In the rsquare of Estes' criteria; (b) routine blood and urine laboratory tests; (c) 24-h urine collection for measurement procedure, the goodness of fit of the model was assessed with Mallows' Cp statistic 26 and Akaike's of sodium and creatinine excretion; (d) blood specimens for plasma renin activity (PRA) and plasma information criterion.
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ANP; and (e) baseline blood pressure (BP) measurements.
Results
Patients were then randomized to receive either atenolol 50-100 mg/day (n = 9) or zofenopril 15-Our study population consisted of 34 middle-aged subjects (57 ± 2 years, range 33-76) with a history of 60 mg/day (n = 25). The randomization was doubleblind and designed to obtain approximately two essential hypertension for 13 ± 1 (2-28) years. There were 25 Hispanic and 9 black patients; 88% were patients on zofenopril for each one on atenolol. This decision was made due to the reported larger variafemale. All subjects had been previously treated with a variety of antihypertensive agents. Creatinine bility of ANP responses to ACE-inhibitors compared to beta-blockers (see Introduction). The dosages of clearance was 1.48 ± 0.08 (0.72-2.65) mL/s, retinopathy (Keith-Wagener grades I or II) was present in both agents were titrated according to a pre-specified schedule with a goal diastolic BP (DBP) of 92 91% and electrocardiographic evidence for LVH (Estes' score у5) in 21%. mm Hg or less. After 10 weeks on therapy, all studies described above were repeated, with the excep-BP and heart rates, 4 weeks after discontinuation of treatment and maintenance on placebo, were 173 tion of the 24-h urine collection.
Blood samples for PRA and ANP were obtained ± 4 (130-214)/103 ± 1 (95-110) mm Hg and 79 ± 2 (50-108) bpm, respectively. PRA was 0.19 ± 0.03 between mid-morning and noon, after the patients had been at least 2 h in the upright position. Blood (0.00-0.94) ngA I /L/s and the prevalence of low renin essential hypertension (by indexing PRA to urine for PRA was collected in EDTA-containing, chilled tubes which were immediately centrifuged. Plasma sodium excretion according to Laragh et al 28 ) was 58%. Plasma level of ANP at the end of the placebo was separated into plastic vials and kept frozen at period was 56 ± 7 (14 -224) pg/ml. This value was shows that all BP reductions were statistically significant with the exception of systolic BP (SBP) in slightly but not significantly higher than that of 29 controls in our laboratory (41 ± 4, P = 0.07). The the atenolol patients (perhaps due to titration of dosage to DBP or to high prevalence of low-renin individual pretreatment levels of plasma ANP correlated with age (r = 0.44, P Ͻ 0.01), ECG score for hypertension). There was no significant difference in the magnitude of BP reduction in patients with LVH (r = 0.51, P Ͻ 0.002), and serum creatinine (r = 0.67, P Ͻ 0.001), and exhibited a negative correan increase against those with a decrease in plasma ANP by zofenopril (Figure 2, right) . Moreover, there lation with creatinine clearance (r = −0.39, P Ͻ 0.03).
Atenolol increased plasma ANP in eight out of were no correlations between changes in plasma ANP and changes in BP (systolic, diastolic or mean) nine patients and did not change it in the ninth (Figure 1, left) . Plasma concentration of ANP was 47 in either the atenolol or the zofenopril groups. Heart rates before and after atenolol were 76 ± 5 ± 8 pg/ml before, and 89 ± 14 after atenolol. The average increase for the group, 42 ± 9, was signifibpm and 60 ± 4 (⌬ = −16 ± 4, P Ͻ 0.01). The respective values for zofenopril were 81 ± 3 and 82 ± 2 (⌬ cant (P Ͻ 0.002). In contrast with this observation, plasma ANP levels before, 59 ± 9, and after treat-= +1 ± 2, ns). Changes in heart rate did not differ between patients who sustained increases vs ment with zofenopril, 53 ± 6, were not significantly different (⌬ = −6 ± 6 pg/ml, Figure 1, right) . This decreases in plasma ANP by zofenopril; +3 ± 2 vs − occurred as a result of 15 patients exhibiting a decrease and 10 patients sustaining an increase in ANP due to zofenopril. To make apparent the existence of these two subgroups, data of zofenopril patients are plotted with offset points in the Figure. The different effects of atenolol and zofenopril on ANP, and the opposite effects of zofenopril on the subgroups of patients who exhibited increases and decreases of ANP due to this agent, were not due to unwanted differences in patients' characteristics introduced by the randomization. This was assessed by 2 or unpaired t-tests for comparisons between all atenolol and all zofenopril patients, and by 2 tests or one-way analyses of variance for comparisons between the atenolol group and the zofenopril subgroups with increases and decreases in plasma ANP. These analyses failed to detect significant differences in age, duration of hypertension, gender or ethnic distribution, pretreatment body mass index, ± 5/103 ± 1 to 160 ± 6/97 ± 2 mm Hg. Figure 2 (left) 1 ± 2 bpm, respectively. In addition, changes in (normal vs low), predicted the response of ANP to drug therapy. plasma ANP did not correlate with changes in heart rate in either the atenolol or the zofenopril groups.
Multiple linear regression showed that 56% of the variability of the change in ANP produced by treat- Figure 3 depicts the relationships between changes in plasma ANP produced by atenolol and ment was explained by: (1) the therapeutic agent (dummy variables for atenolol = 0 and zofenopril = zofenopril and pretreatment ECG score for LVH (left) and serum creatinine (right). It is apparent from the 1); (2) the pretreatment plasma concentration of ANP; and (3) Changes in plasma ANP during antihypertensive therapy cannot be explained by BP reduction, plasma ANP produced by atenolol and the duration of hypertension (r = 0.74, P Ͻ 0.03).
because they vary depending on the pharmacologic agent employed. This is not surprising, in view of Finally, a negative correlation was found between the change in ANP produced by zofenopril and the the fact that there is no relationship between the degree of BP elevation and plasma ANP in untreated pretreatment plasma levels of this peptide (r = −0.69, P Ͻ 0.001, not shown). Because this correlation mild hypertensives. 30,31 Plasma ANP is only consistently elevated in patients with severe hypertension, involves interrelated variables, its validity was confirmed by use of their orthogonal polynomials. 29 The probably reflecting established target organ damage. 32 Consistent with these observations, in our linear regression, ⌬ANP due to zofenopril = 22 − [0.5 × Pretreatment ANP], predicts that zofenopril will patients there was no correlation between plasma ANP and pre-or post-treatment BPs. Also, changes reduce ANP of hypertensives with pretreatment plasma ANP у45 pg/ml.
in ANP by atenolol and zofenopril were different, despite similar reductions of BP by both agents. Atenolol did not change PRA (0.22 ± 0.08 ngA I /L/s, before and after treatment), probably due
The available families of antihypertensive medications have distinct pharmacologic properties and to inability to detect inhibition of very low baseline PRA in five patients, while zofenopril increased reduce BP via different mechanisms of action; it would be reasonable to expect, therefore, that their PRA from 0.17 ± 0.06 to 0.42 ± 0.11 (⌬PRA = +0.25 ± 0.11, P Ͻ 0.02). When the data for all atenolol and actions on plasma ANP are family-specific. However, multiple observations in hypertensive patients zofenopril patients were combined, the changes in ANP and PRA by these agents were negatively correhave established that this is not the case; diuretics, 33 beta-blockers, 2,6 ACE inhibitors [18] [19] [20] [21] and calcium lated (r = −0.47, P Ͻ 0.01) but this observation was not sustained for the atenolol and zofenopril groups channel blockers, 34, 35 have each been reported to increase, decrease or not modify plasma ANP. These analyzed separately. Moreover, neither PRA before treatment nor the renin status of the patients results could be explained on the basis of differ- ences in the pharmacologic profiles of individual in the rat. 44 Also, infusion of angiotensin II, at pressor 42 or subpressor 45 doses, increases plasma agents within the same family. However, this possibility has also been disproved by reports in which ANP in humans and dogs, respectively. If these direct actions of angiotensin II on ANP were the the same drug produces different effects on plasma ANP. For example, hydrochlorothiazide and the major determinants of the effect of ACE inhibitors, the latter should consistently reduce circulating dihydropyridine calcium channel blocker nifedipine have been shown to increase or decrease circullevels of ANP. Neither previous studies, 11, 13, 15, 19 nor our data with zofenopril support this contention. ating ANP.
33-35
Because pharmacologic properties alone cannot Only 60% of our patients experienced a reduction of ANP by zofenopril, the remainder sustaining the account for the effect of antihypertensives on plasma ANP, we hypothesized that patient-related opposite effect. In congestive heart failure, abnormally high levels factors play a role in this response. Release of ANP reflects increased atrial stretch 36, 37 in essential of ANP due to increased atrial pressures are diminished by afterload reduction with ACE inhibihypertensives. The latter may be caused by impaired relaxation associated with LVH, diastolic left ventors. 10, 12, 17 In chronic renal insufficiency, abnormally high levels of ANP due to volume overload tricular dysfunction in the absence of LVH, 38 systemic volume overload (eg, renal insufficiency 39 ) or are also decreased by ACE inhibitors; in this case probably via increases in renal blood flow and bluntincreased venous return in patients with normal systolic and diastolic left ventricular function. 36 Results ing of aldosterone release, leading to enhanced natriuresis and decreased atrial stretch. 39 Our hypertenof laboratory tests routinely used to assess the presence of either cardiac (eg, CXR and ECG) or renal sive patients as a group did not exhibit a significant change in ANP by zofenopril. However, there were (eg, creatinine clearance) abnormalities have been previously shown to correlate with plasma ANP of relationships between individual changes in ANP and clinical markers of cardiac and renal involveessential hypertensives. 40, 41 In the present study, pretreatment plasma ANP was positively correlated ment. The higher the ECG score for LVH or serum creatinine, the more the reduction in ANP by zofento age, ECG score for LVH and serum creatinine and negatively correlated to creatinine clearance. These opril. These observations suggest that in patients with pre-existing hypertensive target organ damage, observations confirm that routine laboratory tests are sensitive enough to detect hypertensive target organ the haemodynamic actions of zofenopril result in decreased atrial stretch concomitant with BP damage linked to augmented release of ANP from the atria. Therefore, we used these tests to investireduction. The observation that the higher the pretreatment level of ANP, the larger its reduction by gate possible patient-related determinants of the response of ANP to the administration of atenolol zofenopril, is also consistent with this view, because pretreatment ANP of our patients correlated with and zofenopril.
Atenolol doubled plasma ANP in our patients. cardiac and renal markers of hypertensive target organ damage. It is noteworthy that the latter This is consistent with the majority of studies on the effects of beta-blockers on plasma ANP. [1] [2] [3] Because relationship predicted a decrease in ANP by zofenopril in patients with pretreatment ANP у45 pg/ml, noradrenaline infusion 42 and shortening of diastole by tachycardia 43 stimulate release of ANP, blockade a value almost identical to mean plasma ANP in our normotensive controls. of adrenergic beta-receptors or reduction of heart rate by atenolol cannot explain our results. The A different explanation is required for the stimulation of ANP by ACE inhibitors in a subgroup of increase in ANP by atenolol was present in all patients but one. The longer the duration of hyperour patients. It is possible that in hypertensive patients with normal plasma ANP and no cardiac or tension, the higher the ECG score for LVH and the higher the serum creatinine, the larger was the magrenal involvement, the predominant effect of ACE inhibitors on ANP is the blunting of its natriuretic nitude of this increase. These data suggest that the negative inotropic action of atenolol results in action, analogous to what is observed in normal humans. 46 Mild sodium retention may thus lead to increased atrial stretch despite BP reduction, and that the magnitude of this effect depends on the subtle atrial stretch and compensatory release of ANP. Whether this accounted for increased plasma degree of pre-existing target organ damage in individual hypertensive patients. If such were the case, ANP in some of our patients cannot be ascertained in the present study. increased plasma ANP by beta-blockers would not be a primary mediator of their antihypertensive
We conclude that an interaction between the pharmacological properties of the therapeutic agent action 3, 4 but only a compensatory response to increased atrial stretch by these agents. Decreases of and the degree of pre-existing target organ damage of individual hypertensive patients determines the plasma ANP by atenolol and other beta-blockers, reported in a few patients, 40, 42 may be explained if effects of treatment on plasma ANP. The multivariate model in our patients supports this view, and these agents improved severely impaired diastolic relaxation or controlled severe hypertension.
accounts for more than half the variability of the change in ANP due to treatment with atenolol or Improvement in atrial function by these effects may have overcome the untoward atrial consequences of zofenopril. It is therefore possible that the explanation for the conflicting results of multiple studies negative inotropism by beta-blockers. These explanations are speculative and require direct echocardion the actions of antihypertensive agents on plasma ANP can be found in the different clinical characterographic or haemodynamic study for confirmation.
Angiotensin II stimulates gene expression of ANP istics of the recruited patient samples.
